Showing 3771-3780 of 5231 results for "".
- Arcutis Seeks FDA Greenlight to Expand ZORYVE for Children Under 6https://practicaldermatology.com/news/arcutis-seeks-fda-greenlight-to-expand-zoryve-for-children-under-6/2483230/Arcutis Biotherapeutics has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children aged 2 to 5, according to
- Dual-Wavelength Laser Caps Gain Clinical Validation for Hair Density Gainshttps://practicaldermatology.com/news/dual-wavelength-laser-caps-gain-clinical-validation-for-hair-density-gains/2476121/KeraFactor announced that it will be spotlighting its dermatologist-developed hair health solutions this August in recognition of National Hair Loss Awareness Month, according to a news release from the manufacturer. The bran
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl
- OSkin Study: Genetic Risk and Nevus Count Stronger Predictors for NAMhttps://practicaldermatology.com/news/genetic-risk-and-nevus-count-stronger-predictors-for-nam-study-finds/2475635/High nevus density and polygenic susceptibility are more strongly associated with nevus-associated melanoma (NAM) than with de novo melanoma, according to results from a new large-scale, population-based cohort study. The QSk
- Probiotic for Oily and Acne-Prone Skin Gets US Patenthttps://practicaldermatology.com/news/Probiotic-Oily-Acne-Prone-Skin-Gets-US-Patent/2474976/A probiotic for managing oily, acne-prone skin was awarded US Patent No. 12,194,068, Codex Labs announced. In an independent clinical trial at Integrative Skin Solutions Research involving 18 male and female subjects with mild to moderate acne, the measured improvement after 8 weeks of Cod
- First Patient Dosed with GPX4 Modulator Targeting Pathologic Senescent Cellshttps://practicaldermatology.com/news/First-Patient-Dosed-with-GPX4-Modulator-Targeting-Pathologic-Senescent-Cells/2474796/
- Melanoma Risk Model Validated in Global Studyhttps://practicaldermatology.com/news/international-study-strengthens-confidence-in-sentinel-node-prediction-tool/2474126/The Melanoma Institute Australia (MIA) sentinel node (SN) metastasis risk calculator has been validated in a large, multinational cohort, reinforcing its applicability across diverse populations and clinical settings. The MIA
- Researchers Identify Novel IL-17A-Linked Psoriasis Gene and Therapeutic Targethttps://practicaldermatology.com/news/plek-identified-as-novel-il-17a-linked-psoriasis-gene-and-therapeutic-target/2473942/Machine learning and in vivo experimentation have identified
- Registration Opens for the Tell-All Tribune and Genesis Meetingshttps://practicaldermatology.com/news/Registration-Opens-Tell-All-Tribune-Genesis-Meetings/2471850/Registration is open for two Modern Aesthetics meetings that were overwhelmingly popular in 2024 and now will be held on the same weekend, June 20-21, at the W Hotel in Fort Lauderdale, Florida. The Tell-All Tribune: An Aesthetic Think Tank, which was an invitation-only event in its inaugu
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202